By Sindhu Sundar ( August 17, 2015, 8:58 PM EDT) -- The U.S. Food and Drug Administration has made no noteworthy detours in its review of Sprout Pharmaceutical Inc.'s controversial drug flibanserin — the first to treat low sex drive in women — which, attorneys say, shows the agency's final decision on Tuesday will be based on trial data and not cultural commentary....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.